Self-antigen displaying nanoparticles targeting auto-reactive immune factors and uses thereof
The invention provides a composition, and method of use thereof, comprising self-antigen displaying nanoparticles to target auto-reactive immune components for treating and/or preventing the autoimmune diseases associated therewith. The nanoparticles can also be loaded with cytotoxic drugs for targeted cell killing or with immune-tolerizing compounds to normalize the immune regulation.
1. A method for reducing anemia symptoms in a subject, which method comprises:
administering, to a subject in need, an effective amount of a nanoparticle comprising a) an inner core comprising a non-cellular material, and b) an outer surface comprising a plasma membrane isolated from a red blood cell (RBC) comprising a self-antigen that comprises glycophorin A and targets an anti-RBC autoantibody that causes anemia,
wherein said subject suffers from hemolytic anemia caused by opsonization of RBC with said anti-RBC auto-antibody, and said nanoparticle sequesters or neutralizes said anti-RBC autoantibody in said subject and reduces anemia symptoms in said subject.
2. The method of claim 1 , wherein the subject is a human.
3. The method of claim 1 , wherein the inner core comprises a biocompatible or a synthetic material selected from the group consisting of poly(lactic-co-glycolic acid (PLGA), polylactic acid (PLA), polyglycolic acid (PGA), polycaprolactone (PCL), polylysine, and polyglutamic acid.
4. The method of claim 1 , wherein the inner core supports the outer surface.
5. The method of claim 1 , wherein the nanoparticle further comprises a releasable cargo.
6. The method of claim 1 , wherein the nanoparticle has a diameter from about 10 nm to about 10 μm.
7. The method of claim 1 , wherein the nanoparticle substantially lacks constituents of the cell from which the plasma membrane is derived.
8. The method of claim 1 , wherein the nanoparticle substantially maintains natural structural integrity or activity of the plasma membrane or the constituents of the plasma membrane.
9. The method of claim 1 , wherein the nanoparticle is biocompatible or biodegradable.
10. The method of claim 1 , wherein the nanoparticle substantially lacks immunogenicity to the subject.
11. The method of claim 10 , wherein the plasma membrane is isolated from a cell from the same species of the subject.
12. The method of claim 1 , further comprising administering another active ingredient to the subject.
13. The method of claim 1 , wherein the nanoparticle does not comprise a drug payload to suppress normal lymphocytes or immune effector cells in a subject.